Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC – Cancer Therapy Advisor
Oncology Nurse Advisor |
Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC
Cancer Therapy Advisor Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy. ORLANDO, FL – Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity … GUCS 2017: Early Immunotherapy Discontinuation in mRCC |
